Practical management of pulmonary arterial hypertension in the intensive care unit

Pulmonary Hypertension

Volumn , Issue , 2009, Pages 455-461

  Sztrymf, Benjamin ^a   Humbert, Marc ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928013319     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (35)

1. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 2007; 35:1599-1608.
2. Parker MM, McCarthy KE, Oqnibene FP, et al. Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 1990; 97:126-131.
3. Kurzyna M, Zyikowska J, Fijaikowska A, et al. Characteristics and prognosis of patients with decompensated right ventricular failure during the course of pulmonary hypertension. Kardiol Pol 2008; 66:1033-1039.
4. Sztrymf B, Bertoletti L, Hamid AM, et al. Survival and prognostic factors of acute exacerbations of pulmonary arterial hypertension. Eur Respir J 2007; 30 (suppl 51):342.
5. Mercat A, Diehl JL, Meyer G, et al. Hemodynamic effect of fluid loading in acute massive pulmonary embolism. Crit Care Med 1999; 27:540-544.
6. Ozier Y, Dubourg O, Farcot JC, et al. Circulatory failure in acute pulmonary embolism. Intensive Care Med 1984; 10:91-97.
7. Haddad F, Doyle R, Murphy DJ, et al. Right ventricular function in cardiovascular disease: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 2008; 117:1717-1731.
8. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351:1425-1436.
9. Bender KA, Alexander JA, Enos JM, et al. Effects of inhaled nitric oxide in patients with hypoxemia and pulmonary hypertension after cardiac surgery. Am J Crit Care 1997; 6:127-131.
10. Rex S, Schaelte G, Metzelder S, et al. Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. Acta Anaesthesiol Scand 2008; 52:65-72.
11. De Santo LS, Mastroianni C, Romano G, et al. Role of sildenafil in acute post-transplant right ventricular dysfunction: successful experience in 13 consecutive patients. Transplant Proc 2008; 40:2015-2018.
12. Olschewski H, Ghofrani HA, Walmrath D, et al. Recovery from circulatory shock in severe primary pulmonary hypertension with aerosolization of iloprost. Intensive Care Med 1998; 631-634.
13. Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest 2007; 131:977-983.
14. Buckley MS, Feldman JP. Nebulized milrinone use in a pulmonary hypertensive crisis. Pharmacotherapy 2007; 1763-1766.
15. Kindo M, Radovancevic B, Gregoric ID, et al. Biventricular support with the Jarvik 2000 ventricular assist device in a calf model of pulmonary hypertension. ASAIO J 2004; 50:444-450.
16. Kerbaul F, Rondelet B, Motte S, et al. Effects of norepinephrine and dobutamine on pressure-load induced right ventricular failure. Crit Care Med 2004; 32:1035-1040.
17. Layish DT, Tapson VF. Pharmacologic hemodynamic support in massive pulmonary embolism. Chest 1997; 111:218-224.
18. Mebazaa A, Karpati P, Renaud E, et al. Right ventricular failure, from pathophysiology to new treatments. Intensive Care Med 2004; 30:185-196.
19. Kwak YL, Lee CS, Park YH, et al. The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension. Anesthesia 2002; 57:9-14.
20. Rich S, Gubin S, Hart K. The effects of phenylephrine on right ventricular performance in patients with pulmonary hypertension. Chest 1990; 98:1102-1106.
21. Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 2002; 30:2548-2552.
22. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102:865-870.
23. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129:1313-1321.
24. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107:2545-2547.
25. Pieralli F, Olivotto I, Vanni S, et al. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol 2006; 97:1386-1390.
26. Adachi S, Ito H, Ohta Y, et al. Distribution of mRNAs natriuretic peptides in right ventricular hypertrophy after pulmonary arterial banding. Am J Physiol 1995; 268:H162-H169.
27. Torbicki A, Kurzyna M, Kuca P, et al. Detectable cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108:844-848.
28. Meyer T, Binder L, Hruska N, et al. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2000; 36:1632-1636.
29. Mehta NJ, Jani K, Khan IA. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J 2003; 145:821-825.
30. Schrier RW. Water and sodium retention in oedematous disorders: role of vasopressin and aldosterone. Am J Med 2006; 119:S47-S53.
31. Damman K, Navis G, Smilde T, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007; 9:872-878.
32. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium and outcome in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007; 28:980-988.
33. Forfia PR, Mathai SC, Fisher MR, et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 177:1364-1369.
34. Konstam MA, Gheorghiade M, Burnett JC Jr., et al. Effects of oral Tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007; 297:1319-1331.
35. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006; 174:1034-1041.